Business Context and Reporting Period
Akebia Therapeutics, Inc. filed this Form 8-K on March 18, 2019, to announce preliminary financial results for the quarter and fiscal year ended December 31, 2018. The filing also addresses a delay in submitting the Annual Report on Form 10-K for the fiscal year ended December 31, 2018, necessitated by the December 12, 2018, closing of a business combination with Keryx Biopharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notice of preliminary results and a delay in the 10-K filing, with the detailed financial data contained in the referenced press release (Exhibit 99.1) rather than the body of this 8-K.
Material Changes and Corporate Events
- Business Combination: The Company completed a business combination with Keryx Biopharmaceuticals, Inc. on December 12, 2018.
- Filing Delay: The Company announced a delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2018, citing the need for additional time to complete preparation due to the aforementioned business combination.
- Regulatory Compliance: The delay is permitted under Rule 12b-25 of the Securities Exchange Act of 1934, with the Company planning to file within the 15 calendar-day period provided by the rule.
Guidance, Outlook, and Risks
Management commented on corporate accomplishments and plans in the associated press release, but specific guidance or outlook figures are not detailed in this filing text. The primary risk disclosed is the administrative delay in the 10-K filing, which is being managed under the provisions of Rule 12b-25.
Investor Verification Checklist
- Verify the specific preliminary financial results (revenue, net loss, cash position) in the press release dated March 18, 2019 (Exhibit 99.1).
- Confirm the exact date the delayed Form 10-K is filed to ensure compliance with the 15-day extension under Rule 12b-25.
- Review the integration status and financial impact of the Keryx Biopharmaceuticals, Inc. business combination in the upcoming 10-K.